Associate Members

  • GBMA
  • MOPI
Mexican Association of Generic Medicines Read More
Generic and Biosimilar Medicines Association (Australia) Read More
Malaysian Organisation of Pharmaceutical Industries Read More
Brazilian Generic Medicine Drugmakers Association Read More



In an era when increasing demands are being made on the world’s healthcare services, generic and biosimilar medicines provide a major benefit to society by ensuring patient access to quality, safe and effective medicines while reducing the cost of pharmaceutical care.

The International Generic Pharmaceutical Alliance (IGPA) was founded in March 1997 as an international network of generic medicines associations. The name of the organization was changed in September 2015 to the International Generic and Biosimilar Medicines Association (IGBA) to reflect the evolving nature of the industry.


Vision and Mission

Our vision is to promote the widest possible access to generic and biosimilar medicines with high quality, safety and efficacy, support international harmonized pathways for the registration of those medicines, and a strong commitment by members to standards agreed by the International Council for Harmonization (ICH) and WHO accredited regulators.



  • The IGBA Biosimilars Committee has developed a communication slide deck on biosimilar medicines

    2017-11-09 - If you wish to use any part of this slide deck, please contact us at \n This email address is being protected from spambots. You need JavaScript enabled to view it. . We would be happy to share this with Read More
  • Ingrid Schwarzenberger, new Chair of the IGBA Biosimilars Committee

    June 13 2017 - IGBA is pleased to announce today the nomination of Ingrid Schwarzenberger, Head Global Regulatory Affairs at Sandoz Biopharmaceuticals, as the new Chair of the IGBA Biosimilars Committee. Ingrid has played a leading role in the establishment of Read More
  • European Experience and Evidence of Physician-led Switching of Biological Medicines Give Hope to Patients around the World

    March 14, 2017 - On 9th March, IFPMA launched jointly with EFPIA and EBE a position paper entitled Considerations for physicians on switching decisions regarding biosimilars. Physician-led switching of biological medicines is a well-known medical practice. Although data on the frequency Read More
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10

Joint 23rd Medicines for Europe and 20th IGBA Annual Conference

Joint 22nd Medicines for Europe and 19th IGBA Annual Conference

18th Annual IGPA Conference

Contact Info


Rue d'Arlon, 50
B-1000 Brussels, Belgium

Telephone: +32 (0)2 736 84 11
Fax: +32 (0)2 736 74 38
E-mail: This email address is being protected from spambots. You need JavaScript enabled to view it.